2023
DOI: 10.1007/s11596-023-2719-4
|View full text |Cite
|
Sign up to set email alerts
|

EZH2 Contributes to Anoikis Resistance and Promotes Epithelial Ovarian Cancer Peritoneal Metastasis by Regulating m6A

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 32 publications
0
0
0
Order By: Relevance
“…In addition, the chemosensitization effect of HDACIs is also related to the combination of drugs. Besides HDACs, other epigenetic enzymes are abnormally expressed in ovarian cancer and participate in ovarian cancer metastasis [154][155][156], which indicates that the combination of HDACIs and inhibitors of these epigenetic enzymes may improve outcomes for patients. In ovarian cancer, many preclinical studies have found that both single-agent HDACIs and the combination of HDACIs with standard chemotherapeutic drugs have significant inhibitory effects on the cell proliferation and metastasis of ovarian cancer [136,157].…”
Section: Discussionmentioning
confidence: 99%
“…In addition, the chemosensitization effect of HDACIs is also related to the combination of drugs. Besides HDACs, other epigenetic enzymes are abnormally expressed in ovarian cancer and participate in ovarian cancer metastasis [154][155][156], which indicates that the combination of HDACIs and inhibitors of these epigenetic enzymes may improve outcomes for patients. In ovarian cancer, many preclinical studies have found that both single-agent HDACIs and the combination of HDACIs with standard chemotherapeutic drugs have significant inhibitory effects on the cell proliferation and metastasis of ovarian cancer [136,157].…”
Section: Discussionmentioning
confidence: 99%